Ucl2077

Drugs were kept in 500X-1,000X stock solutions and diluted in SFM prior the experiments. (-)-Bicuculline methochloride (BIC; GABA_A receptor antagonist), d(-)-2-amino-5-phosphonopentanoic acid (d-AP5; NMDA receptor antagonist), 6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX; AMPA/kainate receptor antagonist) and bisindolylmaleimide X (BIM-X; protein kinase C blocker) were purchased from Tocris (Bristol, UK) or Cayman Chemical (Ann Arbor, MI). SQ 25236 (adenylyl cyclase blocker) and UCL2077 (slow afterhyperpolarization blocker) were obtained from Tocris. TRAM-34 (KCa3.1 blocker) was obtained by MedChemExpress (Monmouth Juntion, NJ, USA). Rp-cAMPS triethylammonium salt (protein kinase A blocker), charybdotoxin (ChTx; fast afterhyperpolarization blocker) and apamin (medium afterhyperpolarization blocker) were obtained from Sigma (Saint-Louis, MO, USA). PG97-269 and PG99-465 (VPAC1 and VPAC2 blockers, respectively) were obtained from Bachem (Torrance, CA, USA). Cholera toxin (CTX) and wortmannin were obtained from Cayman Chemical. Vasoactive intestinal peptide (VIP) was obtained from Phoenix Pharmaceuticals (Burlingame, CA, USA).

Cocaine HCl was dissolved in sterile saline (0.9% NaCl) and was systemically administered at a dose of 10 mg/kg (i.p.) for behavioral conditioning and 5 mg/kg (i.p.) for reinstatement testing. The inhibitor of cAMP-dependent signaling Rp-2’-O-MB-cAMPs (BIOLOG), the sAHP inhibitor UCL-2077 (Tocris), and the MAPK antagonist U0126 (Tocris) were dissolved in equal parts sterile saline (0.9% NaCl) and dimethyl sulfoxide and were infused bilaterally at 3.33 μg/0.3 μl (Ouyang et al., 2008 (link)), 0.67 μg/0.3 μl (Zhang et al., 2013 (link)) and 1.33 μg/0.3 μl (Schafe et al., 2000 (link)), respectively. Following completion of microinfusion experiments, cannulae placements were histologically verified to be immediately dorsal to PL-mPFC (Supplementary Figure S1).